Get access to our best features

Get access to our best features

Published 1 year ago

ALS patients contend with $158K price tag on new drug

Summary by Ground News

In September, Relyvrio became only the third drug approved in the U.S. for ALS. Patients with insurance coverage say the $158,000 per year price tag is fueling insurance delays or denials. Some patients see themselves shouldering co-payments between $1,000 and $4,000 a month.

0 Articles

0 Articles

All

Left

Center

Right

ALS patients contend with $158K price tag on new drug

In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years.

1 year ago·Sacramento, United States

Read Full Article

ALS patients contend with $158K price tag on new drug

In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years.

1 year ago·Boston, United States

Read Full Article

ALS patients contend with $158K price tag on new drug

In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years.

1 year ago·Cincinnati, United States

Read Full Article

ALS patients contend with $158K price tag on new drug

In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years.

Read Full Article

ALS patients contend with $158K price tag on new drug

In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years.

1 year ago·Louisville, United States

Read Full Article

ALS patients contend with $158K price tag on new drug

In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center30Last Updated1 year agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

KCRA 3

WCVB

WLWT

WMUR

WLKY

WESH

+25

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.